Business
Starpharma hunts for cash as it speeds up COVID nasal spray treatment – Sydney Morning Herald
The Melbourne biotech is in a trading halt as it launches a placement for a COVID treatment it hopes to be ready by next year.
Starpharma shares have been on a tear over the past month since the business started to update the market on progress about the nasal spray. Shares have jumped from $1.41 to $1.60 over the past month.
The nasal spray repurposes Starpharma’s antiviral product SPL7013, which is already used in its sexual health products including condoms. The company hopes the compound will bind to the SARS-COV-2 spike protein and block the virus from attaching to cells.
Earlier this month the company released d…
-
Noosa News24 hours agoMan charged over allegedly abandoning Arnie the German shepherd in car after claiming dog and vehicle were stolen
-
Noosa News23 hours agoAustralia Post reintroduces weekend deliveries for Christmas parcel rush
-
Noosa News17 hours agoSunshine Coast Airport receives green light for major upgrade opening doors to growth jobs and tourism across the region
-
Business22 hours agoWhy this investing expert is calling time on NAB shares